Combination Therapy May Reverse Venetoclax Resistance in Relapsed or Refractory AML
GEN,
After decades in which no novel therapeutic treatments were approved for acute myeloid leukemia (AML), the past few years have…
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195
Overview of attention for article published in Leukemia, February 2003
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (95th percentile)
-
High Attention Score compared to outputs of the same age and source (92nd percentile)
Readers on
- mendeley
- 48 Mendeley